NQO1/SLC711A Assay, Total RNA isolation and running custom TaqMan cards (TLDA) assay on up to 486 PAXgene Blood RNA Samples
NQO1/SLC711A Assay, Total RNA isolation and running custom TaqMan cards (TLDA) assay on up to 486 PAXgene Blood RNA Samples
批准号:
10038627
负责人:
LEONARD FREEDMAND
金额:
$15.0万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-08-31 至 2020-08-30
关键词:
Acute Myelocytic LeukemiaAdolescent and Young AdultAdultAzacitidineBiological AssayBiological MarkersBloodBlood specimenCDT1 GeneCarboplatinChildCustomCytarabineDysmyelopoietic SyndromesGene ExpressionGenesImmunotherapyMeasuresMultiple MyelomaNQO1 geneNon-Small-Cell Lung CarcinomaPaclitaxelPatientsPharmacodynamicsPhaseProteinsProtocols documentationRNARandomizedRefractoryRelapseReverse Transcriptase Polymerase Chain ReactionRunningSamplingUbiquitin Like ProteinsWalkersWhole Bloodbasefeasibility trialfludarabinehealthy volunteerphase 2 studyphase II trialprevent
中文摘要
NCI方案(s): 10247“一项随机II期试验,佩维奈远特联合阿扎胞苷与阿扎胞苷治疗成人复发或难治性急性髓性白血病”;10249《伊沙唑米和佩维奈远治疗复发/难治性多发性骨髓瘤:Ib期试验》;[10246]佩伐尼他和贝利诺他治疗复发/难治性急性髓系白血病或骨髓增生异常综合征;10266《佩onedistat联合卡铂和紫杉醇治疗已接受免疫治疗的晚期NSCLC的2期研究》;ADVL1712 -佩维奈远特联合阿扎胞苷、氟达拉滨和阿糖胞苷治疗复发或难治性急性髓性白血病儿童、青少年和年轻人的可行性研究
英文摘要
NCI Protocol(s): 10247 “A randomized phase II trial of pevonedistat with Azacitidine versus Azacitidine in adult relapsed or refractory acute myeloid leukemia”; 10249 “Ixazomib and Pevonedistat in Relapsed/Refractory Multiple Myeloma Patients: A Phase Ib Trial”; 10246 “Pevonedistat and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome”; 10266 “A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy”; ADVL1712 – “A Feasibility Trial of Pevonedistat Given in Combination with Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia”
NAE activates the ubiquitin-like protein NEDD8 for conjugation to CRLs and, therefore, regulates the proteasomal destruction of CRL substrate proteins. NAE inhibition prevents degradation of CRL substrates (e.g., NRF2, CDT1), leading to their accumulation. To develop a pharmacodynamic assay, Walker et al. (2011) developed a RT-PCR-based assay using blood samples from multiple healthy volunteers that were treated ex vivo with a range of MLN4924 (pevonedistat) concentrations. Eight genes (including the NRF2-regulated genes NQO1 and SLC7A11) displayed a robust induction (>3-fold) in whole blood. This assay is aimed at assessing whether MLN4924 target engagement, as measured by increased NRF2-regulated NQO1 and SLC7A11 gene expression in whole blood by RT-PCR, is a biomarker of MLN4924 activity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DCP - Cancer Prevention Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia) BioRepository
-
批准号:10199869
-
项目类别:
-
资助金额:$3.99万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
Repository for the Family Investigation of Nephropathy & Diabetes
-
批准号:10043394
-
项目类别:
-
资助金额:$4.12万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
TAS::75 0849::TAS INCREMENTAL FUNDING
-
批准号:10038552
-
项目类别:
-
资助金额:$4.87万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
Strategic Scientific Pilot Support
-
批准号:10040640
-
项目类别:
-
资助金额:$168.64万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
Informatics Support at FNLCR
-
批准号:10040668
-
项目类别:
-
资助金额:$3581.76万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
DCP- Cancer Immunoprevention Laboratory Support
-
批准号:10043975
-
项目类别:
-
资助金额:$215.48万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
DCEG- GWAS Studies
-
批准号:10038401
-
项目类别:
-
资助金额:$715.44万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
DCP - COPTRG Support [National Surgical Adjuvant Breast and Bowel Project (NSABP)
-
批准号:10199862
-
项目类别:
-
资助金额:$3.99万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
Eye Exams Associated with Anetumab Ravtansine Administration
-
批准号:10038614
-
项目类别:
-
资助金额:$3.2万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
Biospecimen Collection Proteomic
-
批准号:10040642
-
项目类别:
-
资助金额:$548.12万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
TCGA CLinical Data Update
-
批准号:10043657
-
项目类别:
-
资助金额:$140.65万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
DCEG- Repository Services for epidemiology studies
-
批准号:10038403
-
项目类别:
-
资助金额:$231.33万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
ETCTN Biorepository Specimens to the University of Ottawa
-
批准号:10038619
-
项目类别:
-
资助金额:$4.12万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
RAS Program at FNL
-
批准号:10040657
-
项目类别:
-
资助金额:$908.0万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
DCP Support- HPV16L1/RG1 Virus-Like Particle Vaccine
-
批准号:10043970
-
项目类别:
-
资助金额:$32.2万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
HPV Serology
-
批准号:10040624
-
项目类别:
-
资助金额:$87.43万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
Clin Trl Info Mgt -DCP Enterprise System Knowledge Base (DESK)
-
批准号:10043978
-
项目类别:
-
资助金额:$63.35万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
DCP - COPTRG Support [National Surgical Adjuvant Breast and Bowel Project (NSABP)
-
批准号:10043963
-
项目类别:
-
资助金额:$4.27万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
DCP - Cancer Prevention Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia) BioRepository
-
批准号:10043976
-
项目类别:
-
资助金额:$2.3万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
TAS::75 0849::TAS INCREMENTAL FUNDING
-
批准号:10199838
-
项目类别:
-
资助金额:$17.05万
-
财政年份:2019
-
负责人:LEONARD FREEDMAND
-
依托单位:
海外基金